JP6029280B2 - Ｄ−ペプチドを有する抗−アミロイドβ−ペプチド抗体を製造するための組成物 - Google Patents

Ｄ−ペプチドを有する抗−アミロイドβ−ペプチド抗体を製造するための組成物 Download PDF

Info

Publication number
JP6029280B2
JP6029280B2 JP2011536843A JP2011536843A JP6029280B2 JP 6029280 B2 JP6029280 B2 JP 6029280B2 JP 2011536843 A JP2011536843 A JP 2011536843A JP 2011536843 A JP2011536843 A JP 2011536843A JP 6029280 B2 JP6029280 B2 JP 6029280B2
Authority
JP
Japan
Prior art keywords
peptide
amyloid
antibody
seq
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011536843A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012509295A5 (https=
JP2012509295A (ja
Inventor
ヴィルボルト ディーター
ヴィルボルト ディーター
コアト カーステン
コアト カーステン
ミュラー−シフマン アンドレアス
ミュラー−シフマン アンドレアス
アイリーン フンケ スーザン
アイリーン フンケ スーザン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forschungszentrum Juelich GmbH
Original Assignee
Forschungszentrum Juelich GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forschungszentrum Juelich GmbH filed Critical Forschungszentrum Juelich GmbH
Publication of JP2012509295A publication Critical patent/JP2012509295A/ja
Publication of JP2012509295A5 publication Critical patent/JP2012509295A5/ja
Application granted granted Critical
Publication of JP6029280B2 publication Critical patent/JP6029280B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2011536843A 2008-11-19 2009-11-17 Ｄ−ペプチドを有する抗−アミロイドβ−ペプチド抗体を製造するための組成物 Expired - Fee Related JP6029280B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102008037564A DE102008037564A1 (de) 2008-11-19 2008-11-19 Zusammensetzung zur Herstellung von anti-Amyloid beta-Peptid-Antikörpern mit D-Peptiden
DE102008037564.0 2008-11-19
PCT/EP2009/065308 WO2010057882A2 (de) 2008-11-19 2009-11-17 Zusammensetzung zur herstellung von anti-amyloid beta-peptid-antikörpern mit d-peptiden

Publications (3)

Publication Number Publication Date
JP2012509295A JP2012509295A (ja) 2012-04-19
JP2012509295A5 JP2012509295A5 (https=) 2013-01-17
JP6029280B2 true JP6029280B2 (ja) 2016-11-24

Family

ID=41572521

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011536843A Expired - Fee Related JP6029280B2 (ja) 2008-11-19 2009-11-17 Ｄ−ペプチドを有する抗−アミロイドβ−ペプチド抗体を製造するための組成物

Country Status (6)

Country Link
US (1) US9051364B2 (https=)
EP (1) EP2356144B1 (https=)
JP (1) JP6029280B2 (https=)
CN (1) CN102224168B (https=)
DE (1) DE102008037564A1 (https=)
WO (1) WO2010057882A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102010017130B4 (de) * 2010-05-28 2018-11-29 Forschungszentrum Jülich GmbH Hybrid-Verbindung, deren Verwendung und Verfahren zu deren Herstellung
EP2723363B1 (en) 2011-06-24 2018-08-29 NoNO Inc. Combination therapy for ischemia
US9241970B2 (en) * 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
DK2834643T3 (da) * 2012-04-05 2020-02-03 Forschungszentrum Juelich Gmbh Fremgangsmåde til behandling af blod, blodprodukter og organer
DE102012108598A1 (de) * 2012-09-14 2014-04-10 Forschungszentrum Jülich GmbH Neue, von D3 abgeleitete D-enantiomere Peptide und deren Verwendung
EP2834644B1 (de) * 2012-04-05 2019-08-21 Forschungszentrum Jülich GmbH Polymere, enthaltend multivalente amyloid-beta-bindende d-peptide und deren verwendung
DE102012102998B4 (de) * 2012-04-05 2013-12-05 Forschungszentrum Jülich GmbH Polymere, enthaltend multivalente Amyloid-Beta-bindende D-Peptide und deren Verwendung
DE102014003262A1 (de) 2014-03-12 2015-09-17 Forschungszentrum Jülich GmbH Amyloid-Beta-bindende Peptide und deren Verwendung für die Therapie und die Diagnose der Alzheimerschen Demenz
DE102013016002A1 (de) * 2013-09-26 2015-03-26 Forschungszentrum Jülich GmbH Zyklische, Amyloid-Beta-bindende Peptide und deren Verwendung
EP3747454B9 (de) 2013-09-26 2023-10-04 Priavoid GmbH Amyloid-beta-bindende peptide und diese peptide zur verwendung für die therapie und die diagnose der alzheimerschen demenz
DE102015003676A1 (de) * 2015-03-20 2016-09-22 Forschungszentrum Jülich GmbH Fachbereich Patente Spezifisch A-Beta Spezies bindende Peptide für die Therapie und/oder die Diagnose der Alzheimerschen Demenz
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT71860A (en) 1992-08-27 1996-02-28 Deakin Res Ltd Retro-, inverso-, and retro-inverso synthetic peptide analogues
US6277826B1 (en) * 1996-08-27 2001-08-21 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
ATE366259T1 (de) 1999-03-04 2007-07-15 Praecis Pharm Inc Beta-amyloid-peptidaggregation regulierende peptide mit d-aminosäuren
US6849714B1 (en) * 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
DE10117281A1 (de) * 2001-04-06 2002-10-24 Inst Molekulare Biotechnologie Peptid zur Diagnose und Therapie der Alzheimer-Demenz
US6906169B2 (en) * 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
US20050026165A1 (en) * 2001-05-31 2005-02-03 Cindy Orser Detection of conformationally altered proteins and prions
JP4696079B2 (ja) * 2003-12-17 2011-06-08 ヤンセン アルツハイマー イミュノセラピー Ａβ免疫原性ペプチド担体結合物およびそれの製造方法

Also Published As

Publication number Publication date
CN102224168B (zh) 2015-03-25
DE102008037564A1 (de) 2010-05-20
US20110243949A1 (en) 2011-10-06
EP2356144A2 (de) 2011-08-17
CN102224168A (zh) 2011-10-19
EP2356144B1 (de) 2018-07-04
US9051364B2 (en) 2015-06-09
JP2012509295A (ja) 2012-04-19
WO2010057882A2 (de) 2010-05-27
WO2010057882A3 (de) 2010-07-22

Similar Documents

Publication Publication Date Title
JP6029280B2 (ja) Ｄ−ペプチドを有する抗−アミロイドβ−ペプチド抗体を製造するための組成物
US20230295283A1 (en) N-terminal truncated protofibrils/ oligomers for use in therapeutic and diagnostic methods for alzheimer's
US8697076B2 (en) Antibodies selective for pathological tau dimers and prefibrillar pathological tau oligomers and their uses in treatment, diagnosis and monitoring of tauopathies
EP2808032B1 (en) A beta 1-42 specific monoclonal antibodies with therapeutic properties
CN102459336A (zh) 对β-淀粉样肽的初原纤维形式特异性的人源化抗体
JP2014511174A (ja) Ａｐｏｅ免疫療法
CN101325972B (zh) 具有治疗性质的Aβ1-42特异性单克隆抗体
AU2012244075B2 (en) A beta 1-42 specific monoclonal antibodies with therapeutic properties
HK40057935A (en) Antibodies selective for n-terminaltruncated amyloid-p protofibrils/oligomers
HK1124532B (zh) 具有治疗性质的Aβ1-42特异性单克隆抗体
HK1124532A (en) A beta 1-42 specific monoclonal antibodies with therapeutic properties

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20121119

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140509

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140516

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140609

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140703

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150327

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150410

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20150515

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160614

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161018

R150 Certificate of patent or registration of utility model

Ref document number: 6029280

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees